Clinical trials: Neoplasms Recurrence
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
This is a Phase II, multicenter, open-label, randomized study to compare the efficacy of venetoclax in combination with fulvestrant compared with fulvestrant alone in women with ER+, HER2-negative, locally advanced or Metastatic…
- Trial name
- Veronica (NCT03584009)
- Testing
- Venetoclax, Fulvestrant
- Where
- 40 sites in United States, Australia and 3 more
- Volunteers
- 103 people
- Sponsor
- Hoffmann-La Roche
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This phase II trial is studying the side effects and how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or…
- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT00499252
- Testing
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation
- Where
- 20 sites in United States
- Volunteers
- 51 people
- Sponsor
- Gynecologic Oncology Group
Glioblastoma, Glioblastoma Multiforme
A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma
The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent or progressive glioblastoma after prior antiangiogenic therapy (including anti-VEGF therapy)
- Trial name
- 105GM201 (NCT01564914)
- Testing
- TRC105, Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
This phase II trial studies how well giving temsirolimus together with cetuximab works compared to temsirolimus alone in treating patients with recurrent and/or metastatic head and neck cancer who did not respond to previous…
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Trial name
- MAESTRO HN (NCT01256385)
- Testing
- Cetuximab, Laboratory Biomarker Analysis, Temsirolimus
- Where
- 24 sites in United States, China
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
This phase II trial is for patients with acute lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome or chronic myeloid leukemia who have been referred for a peripheral blood stem cell transplantation to treat…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia
- Trial name
- NCT02220985
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
This is a research study to evaluate two different Lenalidomide doses (15 mg vs. 25 mg) in combination with low dose dexamethasone in patients with relapsed multiple myeloma.
- Trial name
- NCT01380106
- Testing
- Lenalidomide 15mg, Lenalidomide 25mg
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- Boston VA Research Institute, Inc.
Recurrent Non-small Cell Lung Cancer
AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer
This phase II trial is studying how well giving AZD2171 together with pemetrexed disodium works in treating patients with relapsed non-small cell lung cancer.
- Trial name
- NCT00410904
- Testing
- cediranib maleate, pemetrexed disodium
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Endometrial Cancer
Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
This is a phase 1/phase 2a study of the combination of immune checkpoint inhibitor (nivolumab) in combination with the PARP inhibitor (rucaparib) for patients with metastatic castration resistant prostate cancer (mCRPC) and…
- Trial name
- NCT03572478
- Testing
- Rucaparib, Nivolumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Multiple Myeloma
UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus
The purpose of this study is to determine the clinical efficacy of MV-NIS (measles virus-sodium iodide symporter) therapy for people with relapsed/refractory myeloma when given with cyclophosphamide
- Trial name
- NCT02192775
- Testing
- MV-NIS
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Arkansas
Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
This clinical study will assess the safety and tolerability of escalating doses of mRNA-2416 alone and in combination with administered fixed doses of durvalumab in participants with relapsed/refractory solid tumor malignancies…
- Trial name
- NCT03323398
- Testing
- mRNA-2416, Durvalumab
- Where
- 9 sites in United States
- Volunteers
- 79 people
- Sponsor
- ModernaTX, Inc.
Endometrial Cancer
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
This research study is studying a drug combination as a possible treatment for endometrial cancer. The drugs involved in this study are: mirvetuximab soravtansine (IMGN853) pembrolizumab
- Trial name
- NCT03835819
- Testing
- Pembrolizumab, IMGN853
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
High-grade Salivary Gland Carcinoma, High-grade Salivary Gland Mucoepidermoid Carcinoma
Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
Phase II trial to study the effectiveness of lapatinib in treating patients who have recurrent and/or metastatic adenoid cystic cancer or other salivary gland cancers.
- Conditions
- High-grade Salivary Gland Carcinoma, High-grade Salivary Gland Mucoepidermoid Carcinoma, Low-grade Salivary Gland Carcinoma, Low-grade Salivary Gland Mucoepidermoid Carcinoma
- Trial name
- NCT00095563
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma
RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry radiation directly to tumor cells and not harm normal cells.
- Trial name
- NCT00245011
- Testing
- filgrastim, ifosfamide, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase I/IIb trial studies side effects and best dose of atezolizumab when given together with guadecitabine and CDX-1401 vaccine and to see how well they work in treating patients with ovarian, fallopian tube, or…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03206047
- Testing
- Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine
- Where
- 17 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
This phase II trial studies how well erlotinib hydrochloride works in Treating participants with muscle invasive urothelial cancer or urothelial cancer that has come back.
- Conditions
- Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma
- Trial name
- NCT00749892
- Testing
- Erlotinib Hydrochloride
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Angiosarcoma, Metastatic Angiosarcoma
Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study
This phase II trial evaluates the effect of sintilimab in treating patients with angiosarcoma that has spread to nearby tissue or lymph nodes (locally advanced), has spread to other places in the body (metastatic), or has come…
- Conditions
- Locally Advanced Angiosarcoma, Metastatic Angiosarcoma, Recurrent Angiosarcoma
- Trial name
- NCT05026736
- Testing
- Quality-of-Life Assessment, Sintilimab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Renal Cell
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell…
- Trial name
- NCT00244764
- Testing
- GW786034
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 225 people
- Sponsor
- GlaxoSmithKline
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer
This phase II trial is studying how well fenretinide works in treating patients with biochemically (rising PSA level) recurrent hormone-naïve (no previous hormone therapy) prostate cancer.
- Trial name
- NCT00080899
- Testing
- fenretinide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
This phase II trial is studying how well giving tipifarnib together with fulvestrant works as second-line therapy in treating postmenopausal women with hormone receptor-positive inoperable locally advanced or metastatic breast…
- Conditions
- Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT00082810
- Testing
- fulvestrant, tipifarnib
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- NCT04155424
- Testing
- Eculizumab
- Where
- 35 sites in United States, Canada and 5 more
- Volunteers
- 5 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.